Top developments in biosimilars during 2019 - GaBI Journal
Roche faces prospect of second Rituxan biosimilar in US - PMLiVE
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership | World Pharma Today
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership - Drug Discovery and Development
Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market :: Scrip
Drug Channels: The Booming Biosimilar Market of 2020
FDA approves Celltrion, Teva's Rituxan biosimilar, but with a narrow label - MedCity News
Top 25 Biosimilar Drug Manufacturers 2019 - Visiongain Research Report
Teva, Celltrion get FDA nod for biosimilar to Roche's cancer drug Rituxan
Pfizer's rituximab biosimilar gets late-stage trial boost
The First Rituxan Biosimilar Is Expected to Be Approved by FDA – Creative Biolabs rAb Blog
Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma
Teva's (TEVA) Filing for Biosimilar Rituxan Accepted by FDA
Global Rituximab Biosimilar Market Assessment –Clinical Trial/Pipeline Analysis, Brand/Originator Drug Historic Revenue and Forecast 2019- 2027 | Medgadget
Teva launches biosimilar to Roche's Rituxan
Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S. | Fierce Pharma
Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States | Business Wire
Teva teams with Celltrion in $160m biosimilar deal - Globes
Teva launches rituximab biosimilar Truxima in US
Riabni™ (rituximab-arrx) – New biosimilar approval
Celltrion's Truxima (rituximab-abbs) Biosimilar Product Profile
FDA panel unanimously backs Celltrion's Rituxan biosimilar | Fierce Pharma
FDA Approves Celltrion's Truxima, a Biosimilar to Rituxan, for Treatment of Adult Patients with Non-Hodgkin's Lymphoma | Specialty Pharma Journal
The U.S. Biosimilars Market: Shaking The “Laggard” Label | Contract Pharma
Are biosimilars the next frontier in drug development? - STAT
Teva and Celltrion Launch Truxima (biosimilar- rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US
